In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $8.94 in the last session, up 2.00% from day before closing price of $8.77. In other words, the price has increased by $2.00 from its previous closing price. On the day, 2.34 million shares were traded. SPRY stock price reached its highest trading level at $9.0699 during the session, while it also had its lowest trading level at $8.6001.
Ratios:
We take a closer look at SPRY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.66.
On September 04, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $40.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 12 ’25 when JUSTIN CHAKMA bought 30,000 shares for $8.91 per share.
Chakma Justin bought 138,380 shares of SPRY for $1,227,420 on Nov 12 ’25. On Aug 21 ’25, another insider, Lowenthal Richard E, who serves as the PRESIDENT AND CEO of the company, sold 50,000 shares for $14.49 each. As a result, the insider received 724,345 and left with 1,196,494 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 884200768 and an Enterprise Value of 1649997696. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.19 while its Price-to-Book (P/B) ratio in mrq is 5.99. Its current Enterprise Value per Revenue stands at 11.557 whereas that against EBITDA is -18.373.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.82, which has changed by -0.37845498 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $8.05. The 50-Day Moving Average of the stock is -9.01%, while the 200-Day Moving Average is calculated to be -31.88%.
Shares Statistics:
According to the various share statistics, SPRY traded on average about 2.62M shares per day over the past 3-months and 2258360 shares per day over the past 10 days. A total of 98.84M shares are outstanding, with a floating share count of 58.38M. Insiders hold about 40.94% of the company’s shares, while institutions hold 65.44% stake in the company. Shares short for SPRY as of 1761868800 were 19756847 with a Short Ratio of 7.54, compared to 1759190400 on 21690186. Therefore, it implies a Short% of Shares Outstanding of 19756847 and a Short% of Float of 32.560003.
Earnings Estimates
The market rating for ARS Pharmaceuticals Inc (SPRY) is a result of the insights provided by 4.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.27 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.6 and -$1.92 for the fiscal current year, implying an average EPS of -$1.7. EPS for the following year is -$0.73, with 4.0 analysts recommending between -$0.17 and -$1.07.
Revenue Estimates
According to 4 analysts,. The current quarter’s revenue is expected to be $28.89M. It ranges from a high estimate of $31.9M to a low estimate of $26.12M. As of. The current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $86.58MFor the next quarter, 4 analysts are estimating revenue of $27.7M. There is a high estimate of $29M for the next quarter, whereas the lowest estimate is $26.9M.
A total of 4 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $88.1M, while the lowest revenue estimate was $82.31M, resulting in an average revenue estimate of $85.82M. In the same quarter a year ago, actual revenue was $89.15MBased on 7 analysts’ estimates, the company’s revenue will be $193.09M in the next fiscal year. The high estimate is $240M and the low estimate is $117.6M.
